SORLA Cuts Alzheimer's Tau Damage in Mice, Revealing 1 Drug Target
Updated
Updated · ScienceDaily · Jul 20
SORLA Cuts Alzheimer's Tau Damage in Mice, Revealing 1 Drug Target
2 articles · Updated · ScienceDaily · Jul 20
Summary
Science Advances data showed mice engineered to produce extra human SORLA developed less tau buildup, less brain atrophy and healthier neuron connections in a tauopathy model.
The protein appeared to blunt tau hyperphosphorylation and the seeding process that helps malformed tau recruit more proteins into toxic tangles.
Mice lacking Sorl1, the gene that makes SORLA, showed the reverse pattern, with more severe tau-related damage, reinforcing SORLA's protective role.
Cell-level mapping also linked higher SORLA to reduced disease-related gene activity in glial cells and highlighted plexin-B receptors as a possible drug target for repurposed therapies.
The Sanford Burnham Prebys team next plans human-cell graft experiments in mouse brains to test how SORLA mutations behave in a living Alzheimer's-like environment.
A natural protein and a new drug both target the same pathway. Is this the long-awaited breakthrough for treating Alzheimer's disease?
Our brains have a natural defense against Alzheimer's. Can we boost this protective protein through our daily lifestyle choices?
Landmark 2026 Discovery: SORLA’s Protective Role Against Tau Pathology Opens New Alzheimer’s Therapy Pathways
Overview
In July 2026, researchers at Sanford Burnham Prebys made a breakthrough discovery showing that the protein SORLA plays a crucial protective role against tau pathology, a key driver of Alzheimer’s disease. Their findings reveal that SORLA can safeguard the brain from the damaging effects of tau tangles, establishing it as a major factor in neuroprotection. This opens up new directions for research, including exploring how SORLA works in the brain and whether existing drugs can be repurposed to target SORLA pathways. These insights could lead to innovative therapies for Alzheimer’s and related dementias.